Prosensa presenting at JP Morgan Healthcare Conference

This is a press release if there is any additional information we will share this with you.

Prosensa to Present at J.P. Morgan Healthcare Conference

LEIDEN, The Netherlands, Jan 03, 2013 (BUSINESS WIRE) — Prosensa, the private Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that Hans Schikan, Chief Executive Officer, will be presenting at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.

Prosensa’s presentation is scheduled at the Westin St. Francis on Union Square at 4.30pm PST on Monday, January 7, 2013 and will provide a corporate update to the investment community. Prosensa’s lead compound (drisapersen), being developed by GlaxoSmithKline, is currently in late-stage phase III clinical trials for Duchenne muscular dystrophy.


Notes to editors:

About Prosensa

Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA-modulating therapeutics correcting gene expression in diseases with significant unmet need, in particular neuromuscular disorders. Prosensa’s current focus is on developing treatments for Duchenne muscular dystrophy (DMD), Myotonic Dystrophy and Huntington’s disease. In 2009 Prosensa entered into a strategic alliance for part of its DMD exon skipping program with GlaxoSmithKline. Prosensa’s lead compound (drisapersen), being developed by GSK, is currently in late-stage phase III clinical trials. Prosensa is a privately held biopharmaceutical company, backed by a consortium of Abingworth, Gimv, Idinvest Partners, Life Sciences Partners, MedSciences Capital and New Enterprise Associates. For more information, please visit .

Prosensa won the 2012 Emerging Star Award at the European Mediscience Awards and was listed as a Fierce 15 Biotech Company.

SOURCE: Prosensa

        Prosensa enquiries: 
        Luc Dochez +31 71 332 2085 
        Hans Schikan +31 71 332 2100 
        Media enquiries: 
        College Hill Life Sciences 
        Melanie Toyne-Sewell / Anastasios Koutsos / Henry Stanley 
        +44 20 7457 2020 
        Rebecca Skye Dietrich (US enquiries) 
        +1 857 241 0795
Print Friendly, PDF & Email

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.